Skip to main content
Erschienen in: Virchows Archiv 6/2007

01.06.2007 | Original Article

GSTP1 promoter hypermethylation is an early event in breast carcinogenesis

verfasst von: Ji Shin Lee

Erschienen in: Virchows Archiv | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Promoter hypermethylation in precursor lesions of the breast cancer may be biomarkers of cancer risk and targets for cancer chemoprevention. Pi-class glutathione-S-transferases (GSTP1) is inactivated by promoter hypermethylation in invasive breast cancers. However, little is known about epigenetic silencing of GSTP1 gene by promoter hypermethylation in precursor lesions. To determine the significance of GSTP1 promoter hypermethylation in breast carcinogenesis, methylation status of GSTP1 gene was studied by nested methylation-specific polymerase chain reaction, and GSTP1 expression was studied by immunohistochemistry in invasive ductal carcinoma (IDC), ductal carcinoma in situ (DCIS), usual ductal hyperplasia (UDH), and normal breast tissue. GSTP1 promoter hypermethylation was detected in 4/24 (16.7%) of UDH, 18/49 (36.7%) of DCIS, and 14/36 (38.9%) of IDC. No hypermethylation was detected in normal breast tissues. GSTP1 promoter hypermethylation was found to be progressively elevated during breast carcinogenesis (p < 0.01). GSTP1 promoter hypermethylation was associated with loss of GSTP1 expression (p < 0.01 for UDH, p < 0.001 for DCIS and IDC). Our results suggest that GSTP1 promoter hypermethylation is an early event in breast carcinogenesis and appears to functionally silence GSTP1 expression. GSTP1 promoter hypermethylation in the precursor lesions of breast cancer may be used as a target for cancer chemoprevention.
Literatur
1.
Zurück zum Zitat Arai T, Miyoshi Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S (2006) Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res Treat 100:169–176PubMedCrossRef Arai T, Miyoshi Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S (2006) Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res Treat 100:169–176PubMedCrossRef
2.
Zurück zum Zitat Arpino G, Laucirica R, Elledge RM (2005) Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 43:446–457 Arpino G, Laucirica R, Elledge RM (2005) Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 43:446–457
3.
Zurück zum Zitat Bellamy CO, Harrison DJ (1994) Evaluation of glutathione S-transferase pi in non-invasive ductal carcinoma of breast. Br J Cancer 69:183–185PubMed Bellamy CO, Harrison DJ (1994) Evaluation of glutathione S-transferase pi in non-invasive ductal carcinoma of breast. Br J Cancer 69:183–185PubMed
4.
Zurück zum Zitat Chan QK, Khoo US, Chan KY, Ngan HY, Li SS, Chiu PM, Man LS, Ip PP, Xue WC, Cheung AN (2005) Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma. J Mol Diagn 7:8–16PubMed Chan QK, Khoo US, Chan KY, Ngan HY, Li SS, Chiu PM, Man LS, Ip PP, Xue WC, Cheung AN (2005) Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma. J Mol Diagn 7:8–16PubMed
5.
Zurück zum Zitat Cho MH, Yoon JH, Jaegal YJ, Choi YD, Lee JS, Lee JH, Nam JH, Choi C, Lee MC, Park CS, Juhng SW, Min KW (2006) Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. Breast 15:390–398PubMedCrossRef Cho MH, Yoon JH, Jaegal YJ, Choi YD, Lee JS, Lee JH, Nam JH, Choi C, Lee MC, Park CS, Juhng SW, Min KW (2006) Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. Breast 15:390–398PubMedCrossRef
6.
Zurück zum Zitat Coles BF, Kadlubar FF (2003) Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs? Biofactors 17:115–130PubMed Coles BF, Kadlubar FF (2003) Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs? Biofactors 17:115–130PubMed
7.
Zurück zum Zitat Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151PubMedCrossRef Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151PubMedCrossRef
8.
Zurück zum Zitat Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG (1998) Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 58:4515–4518PubMed Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG (1998) Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 58:4515–4518PubMed
9.
Zurück zum Zitat Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, Sukumar S, Argani P (2003) DNA methylation of RASSF1A, HIN-1, RAR-beta, cyclin D2 and twist in in situ and invasive lobular breast carcinoma. Int J Cancer 107:970–975PubMedCrossRef Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, Sukumar S, Argani P (2003) DNA methylation of RASSF1A, HIN-1, RAR-beta, cyclin D2 and twist in in situ and invasive lobular breast carcinoma. Int J Cancer 107:970–975PubMedCrossRef
10.
Zurück zum Zitat Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821–9826PubMedCrossRef Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821–9826PubMedCrossRef
11.
Zurück zum Zitat Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, Wood T, Jeronimo C, Rosenbaum E, Stern J, Yu M, Trink B, Kiviat NB, Sidransky D (2006) Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.J Clin Oncol 24:4262–4269PubMedCrossRef Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, Wood T, Jeronimo C, Rosenbaum E, Stern J, Yu M, Trink B, Kiviat NB, Sidransky D (2006) Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.J Clin Oncol 24:4262–4269PubMedCrossRef
12.
Zurück zum Zitat Huang J, Tan PH, Thiyagarajan J, Bay BH (2003) Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Path 16:558–565CrossRef Huang J, Tan PH, Thiyagarajan J, Bay BH (2003) Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Path 16:558–565CrossRef
13.
Zurück zum Zitat Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG (1994) Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91:11733–11737PubMedCrossRef Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG (1994) Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91:11733–11737PubMedCrossRef
14.
Zurück zum Zitat Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H (2002) Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 160:605–612PubMed Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H (2002) Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 160:605–612PubMed
15.
Zurück zum Zitat Lo PK, Mehrotra J, D’Costa A, Fackler MJ, Garrett-Mayer E, Argani P, Sukumar S (2006) Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. Cancer Biol Ther 5:281–286PubMedCrossRef Lo PK, Mehrotra J, D’Costa A, Fackler MJ, Garrett-Mayer E, Argani P, Sukumar S (2006) Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. Cancer Biol Ther 5:281–286PubMedCrossRef
16.
Zurück zum Zitat O’Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC (1998) Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90:697–703PubMedCrossRef O’Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC (1998) Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90:697–703PubMedCrossRef
17.
Zurück zum Zitat Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, Fuchs CS (2006) Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 8:209–217PubMedCrossRef Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, Fuchs CS (2006) Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 8:209–217PubMedCrossRef
18.
Zurück zum Zitat Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60:5954–5958PubMed Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60:5954–5958PubMed
19.
Zurück zum Zitat Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, Rossiello R, Liguoro G, Seripa D, Gravina C, Rabitti C, Rinaldi M, Nicol T, Tommasi S, Paradiso A, Schittulli F, Altomare V, Fazio VM (2004) Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 10:5349–5354PubMedCrossRef Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, Rossiello R, Liguoro G, Seripa D, Gravina C, Rabitti C, Rinaldi M, Nicol T, Tommasi S, Paradiso A, Schittulli F, Altomare V, Fazio VM (2004) Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 10:5349–5354PubMedCrossRef
20.
Zurück zum Zitat Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, Olaru A, Wang S, Mori Y, Deacu E, Hamilton J, Kan T, Krasna MJ, Beer DG, Pepe MS, Abraham JM, Feng Z, Schmiegel W, Greenwald BD, Meltzer SJ (2005) Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett’s-associated neoplastic progression and predicts progression risk. Oncogene 24:4138–4148PubMed Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, Olaru A, Wang S, Mori Y, Deacu E, Hamilton J, Kan T, Krasna MJ, Beer DG, Pepe MS, Abraham JM, Feng Z, Schmiegel W, Greenwald BD, Meltzer SJ (2005) Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett’s-associated neoplastic progression and predicts progression risk. Oncogene 24:4138–4148PubMed
21.
Zurück zum Zitat Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, Turner R, Taback B (2005) Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 11:2156–2162PubMedCrossRef Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, Turner R, Taback B (2005) Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 11:2156–2162PubMedCrossRef
22.
Zurück zum Zitat Steele VE, Kelloff GJ (2005) Development of cancer chemopreventive drugs based on mechanistic approaches. Mutat Res 591:16–23PubMed Steele VE, Kelloff GJ (2005) Development of cancer chemopreventive drugs based on mechanistic approaches. Mutat Res 591:16–23PubMed
23.
Zurück zum Zitat Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI, Sidransky D (2004) Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 10:5518–5522PubMedCrossRef Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI, Sidransky D (2004) Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 10:5518–5522PubMedCrossRef
24.
Zurück zum Zitat Widschwendter M, Jones PA (2002) DNA methylation and breast carcinogenesis. Oncogene 21:5462–5482PubMedCrossRef Widschwendter M, Jones PA (2002) DNA methylation and breast carcinogenesis. Oncogene 21:5462–5482PubMedCrossRef
25.
Zurück zum Zitat Yang C, Trent S, Ionescu-Tiba V, Lan L, Shioda T, Sgroi D, Schmidt EV (2006) Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression. Cancer Res 66:11649–11658PubMedCrossRef Yang C, Trent S, Ionescu-Tiba V, Lan L, Shioda T, Sgroi D, Schmidt EV (2006) Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression. Cancer Res 66:11649–11658PubMedCrossRef
26.
Zurück zum Zitat Zhong S, Tang MW, Yeo W, Liu C, Lo YM, Johnson PJ (2002) Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res 8:1087–1092PubMed Zhong S, Tang MW, Yeo W, Liu C, Lo YM, Johnson PJ (2002) Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res 8:1087–1092PubMed
Metadaten
Titel
GSTP1 promoter hypermethylation is an early event in breast carcinogenesis
verfasst von
Ji Shin Lee
Publikationsdatum
01.06.2007
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 6/2007
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-007-0421-8

Weitere Artikel der Ausgabe 6/2007

Virchows Archiv 6/2007 Zur Ausgabe

Announcements

Announcements

Neu im Fachgebiet Pathologie